Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide in NASH with Compensated Cirrhosis
NCT03987451Phase 2Completed
- Sponsor
- Novo Nordisk
- Start
- Jun 2019
- Primary completion
- Apr 2021
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 5
01
Overview
A Phase 2 trial of semaglutide in Nonalcoholic steatohepatitis (NASH), sponsored by Novo Nordisk. Started Jun 2019; status: completed.
02
Drugs
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT03987451.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03987451.